KRAS Gene Mutation: Clinical Trials

1 terminated. 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	1	Terminated 1

Follow KRAS Gene Mutation: new trials by email Literature Review of KRAS Gene Mutation trials Research Report on KRAS Gene Mutation

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer SHR-1210, Apatinib, Pemetrexed - NSCLC Stage IV, KRAS Gene Mutation	Phase 2	Terminated	Jiangsu HengRui Medicine Co., Ltd.	25	2019-07-11	2025-07-04

Narrower conditions

Carcinoma, Non-Small-Cell Lung (1)

Broader conditions

Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)  ·  Thoracic Neoplasms (1)

Interventions

Carboplatin (1)  ·  Pemetrexed (1)  ·  apatinib (1)  ·  camrelizumab (1)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (1)

Countries

China (1)

Top investigators

Jianjun Zou, MD, PhD (1)  ·  Shun Lu, MD, PhD (1)